If you or someone you care for has been diagnosed with EGFR+* NSCLC, check out the information below to better understand treatment options with RYBREVANT FASPRO™ or RYBREVANT®.
About NSCLC
NSCLC is the most common type of lung cancer—it makes up about 85% of all lung cancer cases.
Lung cancer, including NSCLC, occurs when cancer cells form into tumors in the tissues of the lung. When cells from the tumor travel through the body, the cancer spreads. When this happens, it’s called “advanced” or “metastatic” cancer.
Learn more about your NSCLC with biomarker testing
Once an NSCLC diagnosis has been made, biomarker testing is used to help your doctor identify the treatment that best fits your needs. A biomarker is a sign in your body that helps doctors understand your health and your cancer. By testing for certain biomarkers, your doctor can understand what kind of genetic change, or mutation, your cancer has. Your doctor will then use that information to choose the most appropriate treatment.
For example, if tests show that your cancer has certain changes—like EGFR exon 19 deletions, exon 21 L858R substitution mutations, or EGFR exon 20 insertion mutations—then RYBREVANT FASPRO™ or RYBREVANT® might be a good option for you. Be sure to ask your doctor about biomarker testing at your next appointment.
Find out more about EGFR mutations
A protein called EGFR (epidermal growth factor receptor) is found on both healthy cells and cancer cells. This protein is important because it helps healthy cells grow and survive. But sometimes harmful changes in EGFR proteins, known as mutations, can make cancer cells grow and spread in the body.
RYBREVANT FASPRO™ and RYBREVANT® can be used by itself or with other medicines to treat advanced NSCLC that has certain EGFR mutations and has spread to other parts of the body (metastatic) or cannot be removed by surgery:
EGFR exon 19 deletions or exon 21 L858R substitution mutations, which account for 80% to 90% of all EGFR mutations in NSCLC.
EGFR exon 20 insertion mutations, which are rare but still the third most common EGFR mutations in NSCLC.
